{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T17:55:33Z","timestamp":1785779733310,"version":"3.56.0"},"reference-count":29,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2026,8,2]],"date-time":"2026-08-02T00:00:00Z","timestamp":1785628800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"National Institutes of Health\/National Cancer Institute","award":["P01 CA193124"],"award-info":[{"award-number":["P01 CA193124"]}]},{"name":"National Institutes of Health\/National Cancer Institute","award":["R01 CA093729"],"award-info":[{"award-number":["R01 CA093729"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Genes"],"abstract":"<jats:p>Background\/Objectives: Cisplatin is used in the treatment of ovarian cancer; however, the development of resistance, often due to the efficient repair of cisplatin-induced DNA damage, remains a major barrier to effective therapy. Among these lesions, DNA interstrand crosslinks (ICLs) are particularly cytotoxic because they prevent DNA replication and transcription. HMGB2, a member of the high-mobility group box (HMGB) protein family, can bind DNA lesions and has been implicated in genome maintenance and DNA repair. This study investigated whether HMGB2 contributes to the processing of cisplatin-induced DNA damage and modulates cisplatin sensitivity in human ovarian cancer cells. Methods: HMGB2 expression was suppressed by siRNA in cisplatin-sensitive A2780 and cisplatin-resistant CP70 human ovarian cancer cells. Cellular responses to cisplatin were assessed using clonogenic survival assays, cell cycle analysis, Western blotting, slot blot analysis, and modified alkaline comet assays. Results: HMGB2 depletion reduced clonogenic survival in cisplatin-resistant CP70 cells and increased the sub-G1 population, indicating enhanced apoptotic DNA fragmentation following cisplatin treatment in both cell lines. Depletion of HMGB2 resulted in increased persistence of cisplatin\u2013DNA adducts and impaired ICL processing, as demonstrated by persistent DNA damage over time and reduced ICL unhooking efficiency. DNA damage response signaling following cisplatin treatment was also altered by HMGB2 depletion in both cell lines, whereas the expression levels of key DNA repair proteins were unchanged. Conclusions: Our findings demonstrate that HMGB2 is involved in the cellular response to cisplatin treatment by promoting the efficient processing of cisplatin DNA adducts, particularly ICLs, thereby modulating cisplatin sensitivity in human ovarian cancer cells. These findings suggest that targeting HMGB2 may serve as a potential therapeutic strategy for overcoming cisplatin resistance in ovarian cancer.<\/jats:p>","DOI":"10.3390\/genes17080916","type":"journal-article","created":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T17:26:52Z","timestamp":1785778012000},"page":"916","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["HMGB2 Impacts Cisplatin-Induced DNA Adduct Processing in Chemoresistant Ovarian Cancer Cells"],"prefix":"10.3390","volume":"17","author":[{"given":"Van","family":"Huynh","sequence":"first","affiliation":[{"name":"Division of Pharmacology and Toxicology, College of Pharmacy, The University of Texas at Austin, Dell Pediatric Research Institute, 1400 Barbara Jordan Boulevard, Austin, TX 78723, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guliang","family":"Wang","sequence":"additional","affiliation":[{"name":"Division of Pharmacology and Toxicology, College of Pharmacy, The University of Texas at Austin, Dell Pediatric Research Institute, 1400 Barbara Jordan Boulevard, Austin, TX 78723, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6958-5073","authenticated-orcid":false,"given":"Karen M.","family":"Vasquez","sequence":"additional","affiliation":[{"name":"Division of Pharmacology and Toxicology, College of Pharmacy, The University of Texas at Austin, Dell Pediatric Research Institute, 1400 Barbara Jordan Boulevard, Austin, TX 78723, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,8,2]]},"reference":[{"key":"ref_1","first-page":"e70043","article-title":"Cancer statistics, 2026","volume":"76","author":"Siegel","year":"2026","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"191","DOI":"10.6004\/jnccn.2021.0007","article-title":"Ovarian Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology","volume":"19","author":"Armstrong","year":"2021","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"e1257","DOI":"10.1038\/cddis.2013.428","article-title":"Systems biology of cisplatin resistance: Past, present and future","volume":"5","author":"Galluzzi","year":"2014","journal-title":"Cell Death Dis."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1186\/s40064-016-2660-0","article-title":"Management of relapsed ovarian cancer: A review","volume":"5","author":"Giornelli","year":"2016","journal-title":"SpringerPlus"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.ejphar.2014.07.025","article-title":"Cisplatin in cancer therapy: Molecular mechanisms of action","volume":"740","author":"Dasari","year":"2014","journal-title":"Eur. J. Pharmacol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1146\/annurev.biochem.73.011303.073723","article-title":"Molecular mechanisms of mammalian DNA repair and the DNA damage checkpoints","volume":"73","author":"Sancar","year":"2004","journal-title":"Annu. Rev. Biochem."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/nrc3088","article-title":"DNA interstrand crosslink repair and cancer","volume":"11","author":"Deans","year":"2011","journal-title":"Nat. Rev. Cancer"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.phrs.2016.01.001","article-title":"Cisplatin resistance and opportunities for precision medicine","volume":"106","author":"Amable","year":"2016","journal-title":"Pharmacol. Res."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1182\/blood-2009-06-230094","article-title":"High-mobility group protein HMGB2 regulates human erythroid differentiation through trans-activation of GFI1B transcription","volume":"115","author":"Laurent","year":"2010","journal-title":"Blood"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1038\/21460","article-title":"Basis for recognition of cisplatin-modified DNA by high-mobility-group proteins","volume":"399","author":"Ohndorf","year":"1999","journal-title":"Nature"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.bbagrm.2009.09.008","article-title":"HMGB proteins: Interactions with DNA and chromatin","volume":"1799","author":"Stros","year":"2010","journal-title":"Biochim. Biophys. Acta-Gene Regul. Mech."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1002\/mc.70074","article-title":"HMGB1 Assists in Overcoming Cisplatin Resistance in Chemoresistant Human Ovarian Cancer Cells","volume":"65","author":"Huynh","year":"2026","journal-title":"Mol. Carcinog."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"3185","DOI":"10.1158\/0008-5472.CAN-19-0542","article-title":"Targeting the High-Mobility Group Box 3 Protein Sensitizes Chemoresistant Ovarian Cancer Cells to Cisplatin","volume":"79","author":"Mukherjee","year":"2019","journal-title":"Cancer Res."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.tibs.2012.09.003","article-title":"The high mobility group box: The ultimate utility player of a cell","volume":"37","author":"Malarkey","year":"2012","journal-title":"Trends Biochem. Sci."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1038\/s41419-021-03959-3","article-title":"HMGB2 orchestrates mitotic clonal expansion by binding to the promoter of C\/EBPbeta to facilitate adipogenesis","volume":"12","author":"Chen","year":"2021","journal-title":"Cell Death Dis."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.dnarep.2015.09.015","article-title":"High mobility group (HMG) proteins: Modulators of chromatin structure and DNA repair in mammalian cells","volume":"36","author":"Reeves","year":"2015","journal-title":"DNA Repair"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S0968-0004(01)01801-1","article-title":"HMG1 and 2, and related \u2018architectural\u2019 DNA-binding proteins","volume":"26","author":"Thomas","year":"2001","journal-title":"Trends Biochem. Sci."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"17345","DOI":"10.1002\/jcb.28998","article-title":"High-mobility group box 2 promoted proliferation of cervical cancer cells by activating AKT signaling pathway","volume":"120","author":"Zhang","year":"2019","journal-title":"J. Cell Biochem."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"101977","DOI":"10.1016\/j.tranon.2024.101977","article-title":"HMGB2 is a biomarker associated with poor prognosis promoting radioresistance in glioma by targeting base excision repair pathway","volume":"45","author":"Han","year":"2024","journal-title":"Transl. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"5511","DOI":"10.1158\/1078-0432.CCR-10-0825","article-title":"Overexpression of high-mobility group box 2 is associated with tumor aggressiveness and prognosis of hepatocellular carcinoma","volume":"16","author":"Kwon","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1093\/neuonc\/not078","article-title":"High-mobility group box 2 is associated with prognosis of glioblastoma by promoting cell viability, invasion, and chemotherapeutic resistance","volume":"15","author":"Wu","year":"2013","journal-title":"Neuro-Oncology"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1093\/nar\/gkv1183","article-title":"HMGB1 interacts with XPA to facilitate the processing of DNA interstrand crosslinks in human cells","volume":"44","author":"Mukherjee","year":"2016","journal-title":"Nucleic Acids Res."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/978-1-0716-0323-9_7","article-title":"Analysis of DNA Interstrand Cross-Links and their Repair by Modified Comet Assay","volume":"2119","author":"Swift","year":"2020","journal-title":"Methods Mol. Biol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1158\/1078-0432.CCR-07-2238","article-title":"Platinum resistance: The role of DNA repair pathways","volume":"14","author":"Martin","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"e478s","DOI":"10.6061\/clinics\/2018\/e478s","article-title":"DNA repair pathways and cisplatin resistance: An intimate relationship","volume":"73","author":"Rocha","year":"2018","journal-title":"Clinics"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"7265","DOI":"10.1038\/sj.onc.1206933","article-title":"Cisplatin: Mode of cytotoxic action and molecular basis of resistance","volume":"22","author":"Siddik","year":"2003","journal-title":"Oncogene"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1002\/pmic.201400338","article-title":"Silencing of high-mobility group box 2 (HMGB2) modulates cisplatin and 5-fluorouracil sensitivity in head and neck squamous cell carcinoma","volume":"15","author":"Syed","year":"2015","journal-title":"Proteomics"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Starkova, T., Polyanichko, A., Tomilin, A.N., and Chikhirzhina, E. (2023). Structure and Functions of HMGB2 Protein. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24098334"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Starkova, T.Y., Polyanichko, A.M., Artamonova, T.O., Tsimokha, A.S., Tomilin, A.N., and Chikhirzhina, E.V. (2023). Structural Characteristics of High-Mobility Group Proteins HMGB1 and HMGB2 and Their Interaction with DNA. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24043577"}],"container-title":["Genes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4425\/17\/8\/916\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T17:28:20Z","timestamp":1785778100000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4425\/17\/8\/916"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,2]]},"references-count":29,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["genes17080916"],"URL":"https:\/\/doi.org\/10.3390\/genes17080916","relation":{},"ISSN":["2073-4425"],"issn-type":[{"value":"2073-4425","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,2]]}}}